EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of CD33+ acute myeloid leukemia and myelodysplastic syndrome with gemtazumab ozogamicin, IL-11 and low weight heparin Preliminary results



Treatment of CD33+ acute myeloid leukemia and myelodysplastic syndrome with gemtazumab ozogamicin, IL-11 and low weight heparin Preliminary results



Blood 102(11): 256b, November 16



Gemtazumab ozogamicin (Mylotarg) is an antibody-targeted chemotherapeutic agent consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent antitumor antibiotic. In this study eleven (11) patients (age range: 24-78 years) with diagnosis of CD33+ acute myeloid leukemia were treated with Mylotarg: one patient with de novo AML reluctant to chemotherapy, one old man with de novo AML, two patients refractory to chemotherapy, two patients in relapse, three patients with AML secondary to a myelodysplastic syndrome (MDS), one patient with secondary AML, one patient in relapse after transplant of autologous progenitor cells. The Gemtazumab Ozogamicin (9 mg/m2) was administered intravenously in two doses given two weeks apart as induction treatment and then every 6 weeks as maintenance. Low weight heparin and IL-11 were used in some of these patients. Transient fever and chills were seen only in one patient, while transient elevations of AST/ALT, bilirubin and moderately myelosuppression were seen in all patients. The patient with de novo AML was a 65 years-old woman who suffered of congenital impaired hearing. This patient entered in complete remission after two doses of Mylotarg; she received maintenance doses during 8 months. She had a good quality of life for 8 months and then relapsed. Chemotherapy was administered but she did not respond to it and she died in relapse. Another patient, a 50 years-old woman refractory to chemotherapy also entered in complete remission with Mylotarg and survived 9 months with good quality of life; then she relapsed, did not respond to chemotherapy and died. One patient a 78 years-old man with de novo AML did not respond to Mylotarg. One 28 years-old patient refractory to chemotherapy entered in complete remission with Mylotarg; he has been in complete remission for two years. One patient, a 24 years-old woman in third relapse only got partial remission. Three patients with AML secondary to MDS, one with secondary leukemia, one patient with AML-M3 in second relapse and one patient in relapse post transplant of autologous progenitor cells did not respond to Mylotarg. The IL-11 helped to decreased the number of platelets transfusion in the myelosuppression phase post-Mylotarg and the low MW heparin prevented thrombotic episodes as VOD. In summary 11 patients with AML were treated with Mylotarg. A complete remission was obtained in three of them with a remission period ranging from 8 to 18. These patients had a good quality of life. Mylotarg alone does not increase the rate of survival in AML patients, but it could be useful in combination with chemotherapy in new protocols. IL-11 decreases the requirement of platelets post Mylotarg and low molecular heparin probably prevents VOD.

(PDF 0-2 workdays service: $29.90)

Accession: 035980354

Download citation: RISBibTeXText



Related references

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clinical Cancer Research 11(19 Pt 2): 7164s-7170s, 2005

Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anti-Cancer Drugs 13(7): 685-692, 2002

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia 12(4): 244-251, 2013

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry 13(1): 47-58, 2002

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg(R)) treatment in acute myeloid leukemia patients. Leukemia (Basingstoke) 18(5): 983-988, 2004

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 106(4): 1183-1188, 2005

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology 19(13): 3244-3254, 2001

Clinical development of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia. 2006

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica 97(2): 219-226, 2012

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. International Journal of Hematology 89(4): 460-469, 2009

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood 127(17): 2157-2160, 2016

Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2): 258-264, 2007

Cytocidal effects of gemtuzumab ozogamicin (CMA-676) on CD33-expressing acute myeloid leukemia cells, analysis P-glycoprotein and CD34 expression. Japanese Journal of Clinical Hematology 43(5): 309-315, 2002

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104(7): 1442-1452, 2005

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opinion on Biological Therapy 8(4): 527-540, 2008